Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults

• Status: Recruiting
• Trial end date: 2027-02-01
• Target enrollment: 0
• Participant gender: All

Summary

After consolidation therapy adult patients (≥18 yr) with Ph-negative ALL will be treated with continuation chemotherapy or allogeneic hematopoietic stem cell transplantation (alloHSCT) according to both measurable residual disease (MRD) and results of genetic study performed at baseline.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: PETHEMA Foundation
• Treatments: Cytarabine; Mercaptopurine; Methotrexate

Criteria

Inclusion Criteria:

• Patients 18-60 yr with de novo Ph-neg ALL

• Eastern Cooperative Oncology Group (ECOG) 0-2 (or >2 if due to ALL)

• Informed consent

Exclusion Criteria:

• Mature B-ALL, Ph+ ALL or blast crisis of chronic myeloid leukemia (CML), ALL of ambiguous lineage

• ECOG >2 not due to ALL

• Impaired cardiac, respiratory, hepatic or renal function not due to ALL

• Pregnancy

• HIV positivity

• Severe psychiatric disease

• Negative to sign informed consent.